GSK Shoulder-To-Shoulder With CureVac Over COVID-19 Vaccine U-Turn
Focus On Second-Generation After EMA Filing Withdrawal
The UK major is delighted with the German biotech's decision to throw in the regulatory towel with CVnCoV and concentrate on the firms' collaboration to development a second-generation COVID-19 vaccine. However, GSK is insisting that the partners look at both modified as well as unmodified mRNA approaches, a significant change of strategy for CureVac.
You may also be interested in...
Patients 18-60 had a protection rate of 53%, but there were too few cases among those older than 60 – a crucial subgroup – in HERALD to draw conclusions about the vaccine’s efficacy among older people.
The Swiss major's oncology business performed well in the third quarter with Kisqali sales catching the eye despite the specific problems that the pandemic has brought for breast cancer patients.
CEO Vas Narasimhan sees Novartis very much as an innovative company so the long-awaited strategic review of Sandoz suggests that the generics/biosimilars business could be spun off or sold fairly soon.